Form 4: Quest Diagnostics CEO James E. Davis Sells Shares Under 10b5-1 Plan

Quest Diagnostics CEO James E. Davis sold a portion of his common stock holdings on April 2, 2025, under a pre-arranged Rule 10b5-1 sales plan.

Summary

• On April 2, 2025, James E. Davis, the CEO and President of Quest Diagnostics, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 sales plan.
• A total of 36,504 shares were sold in multiple transactions at varying prices.
• The prices ranged from $167.3326 to $169.8434 per share.
• Following the reported transactions, Davis directly owns 127,623 shares of Quest Diagnostics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting insider trading activity. It is neutral in tone and doesn't inherently indicate positive or negative sentiment.

Positives

• The sales were executed under a pre-arranged Rule 10b5-1 plan, which is a legal and transparent way for insiders to sell shares.

Risks

• While the sales were conducted under a 10b5-1 plan, large insider sales can sometimes be perceived negatively by the market.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Insider trading activity is always closely watched in the healthcare industry, as it can provide insights into management's perspective on the company's future prospects. However, sales under 10b5-1 plans are generally viewed as less informative since they are pre-planned.

Comparison to Industry Standards

• Comparing the CEO's trading activity to peers like Laboratory Corporation of America (LH) or other diagnostic companies could provide context, but this document alone doesn't offer enough information for a comprehensive comparison.
• It's common for executives at publicly traded companies to have 10b5-1 plans in place to manage their stock sales.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, depending on how the market interprets the transaction.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates

Keywords

Quest Diagnostics, insider trading, Form 4, James E. Davis, CEO, stock sale, Rule 10b5-1, DGX